[1] Heo S, Park HJ, Lee SS. Prognostication of hepatocellular carcinoma using artificial intelligence. Korean J Radiol, 2024,25(6):550-558. [2] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol, 2025,82(2):315-374. [3] Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin, 2023,73(2):198-222. [4] 刘雅欣,赵文慧,鲁佳乐,等. 多模态磁共振功能成像及磁共振影像组学在肿块型肝内ICC诊断及预后的应用进展. 中华肝胆外科杂志,2025,31(1):73-76. [5] Yang L, Niu K, Wang J, et al. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD. J Hepatol, 2024,81(4):651-666. [6] Zheng J, Xia Y, Xu A, et al. Combined model based on enhanced CT texture features in liver metastasis prediction of high-risk gastrointestinal stromal tumors. Abdom Radiol (NY), 2022,47(1):85-93. [7] Suzuki M, Hayashi T, Nashiki K, et al. Influence of Gd-EOB-DTPA on proton-density fat fraction in the liver using chemical shift-encoded magnetic resonance imaging at 3-T. Radiol Phys Technol, 2024,17(3):637-644. [8] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版). 中华肝脏病杂志,2024,32(7):581-630. [9] Sheng R, Zhang Y, Wang H, et al. A multi-center diagnostic system for intrahepatic mass-forming cholangiocarcinoma based on preoperative MRI and clinical features. Eur Radiol, 2024,34(1):548-559. [10] Johnson P, Zhou Q, Dao DY, et al. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2022,19(10):670-681. [11] Wu H, Liang Y, Wang Z, et al. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma. Acta Radiol, 2023,64(3):926-935. [12] Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol, 2023,20(12):864-884. [13] Jeon U, Woo JH, Jeong DY, et al. Automatic virtual contrast-enhanced CT synthesis using dual-energy CT and residual U-Net with attention module for detecting pulmonary hilar lymphadenopathy. Acad Radiol, 2025,32(3):1718-1724. [14] Liu Q, Zeng F, Peng C, et al. Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series. Transl Lung Cancer Res, 2024,13(5):1101-1109. [15] Goujon A, Khene ZE, Thenault R,et al. Contrast-enhanced CT texture analysis for the prediction of delayed graft function following kidney transplantation from cadaveric donors. Prog Urol, 2022,32(12):868-874. [16] Huang Z, Zhu RH, Li SS, et al. Comparison of sonazoid-contrast-enhanced ultrasound and Gd-EOB-DTPA-enhanced MRI for predicting microvascular invasion in hepatocellular carcinoma. Ultrasound Med Biol, 2024,50(9):1339-1345. [17] Cheng J, Li X, Wang L, et al. Evaluation and prognostication of Gd-EOB-DTPA MRI and CT in patients with macrotrabecular-massive hepatocellular carcinoma. J Magn Reson Imaging, 2024,59(6):2071-2081. [18] Crimì F, Zanon C, Cabrelle G, et al. Contrast-enhanced CT texture analysis in colon cancer: correlation with genetic markers. Tomography, 2022,8(5):2193-2201. [19] Xia F, Guo F, Liu Z, et al. Enhanced CT combined with texture analysis for differential diagnosis of pleomorphic adenoma and adenolymphoma. BMC Med Imaging, 2023,23(1):169. [20] Teo T, Chawla A. The cloud sign of mass-forming intrahepatic cholangiocarcinoma. Abdom Radiol (NY), 2020,45(1):237-238. |